| Dr Michael Karsy, MD/PHD | |
|
1650 Huntingdon Pike Ste 261, Meadowbrook, PA 19046-8008 | |
| (844) 464-6387 | |
| (215) 239-3037 |
| Full Name | Dr Michael Karsy |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 11 Years |
| Location | 1650 Huntingdon Pike Ste 261, Meadowbrook, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972845345 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | MD469584 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Mary Medical Center | Langhorne, PA | Hospital |
| Holy Redeemer Hospital And Medical Center | Meadowbrook, PA | Hospital |
| Crozer Chester Medical Center | Upland, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hr Physician Services | 0042109902 | 143 |
News Archive
The Clalit Research Institute, in collaboration with researchers from Harvard University, analyzed one of the world's largest integrated health record databases to examine the effectiveness of the Pfizer/BioNTech BNT162B2 vaccine against the Delta variant of SARS-CoV-2 among adolescents.
Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has launched new education, distribution, sampling and reimbursement programs for TIMOPTIC(R) in OCUDOSE(R), the only preservative-free medication for glaucoma available in the United States. Aton acquired the U.S. marketing rights in February to the TIMOPTIC product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle glaucoma.
Western New England College Research Presented at 2nd Pan-American/Iberian Meeting on Acoustics. To keep soldiers in the battlefield healthy, the U.S. Army is exploring new ways to detect harmful bacteria in water.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have successfully combined cellular therapy and gene therapy in a mouse-model system to develop a viable treatment strategy for breast cancer that has spread to a patient's brain.
› Verified 9 days ago
| Entity Name | Hr Physician Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881696698 PECOS PAC ID: 0042109902 Enrollment ID: O20040311000028 |
News Archive
The Clalit Research Institute, in collaboration with researchers from Harvard University, analyzed one of the world's largest integrated health record databases to examine the effectiveness of the Pfizer/BioNTech BNT162B2 vaccine against the Delta variant of SARS-CoV-2 among adolescents.
Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has launched new education, distribution, sampling and reimbursement programs for TIMOPTIC(R) in OCUDOSE(R), the only preservative-free medication for glaucoma available in the United States. Aton acquired the U.S. marketing rights in February to the TIMOPTIC product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle glaucoma.
Western New England College Research Presented at 2nd Pan-American/Iberian Meeting on Acoustics. To keep soldiers in the battlefield healthy, the U.S. Army is exploring new ways to detect harmful bacteria in water.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have successfully combined cellular therapy and gene therapy in a mouse-model system to develop a viable treatment strategy for breast cancer that has spread to a patient's brain.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Karsy, MD/PHD 1650 Huntingdon Pike Ste 261, Meadowbrook, PA 19046-8008 Ph: (844) 464-6387 | Dr Michael Karsy, MD/PHD 1650 Huntingdon Pike Ste 261, Meadowbrook, PA 19046-8008 Ph: (844) 464-6387 |
News Archive
The Clalit Research Institute, in collaboration with researchers from Harvard University, analyzed one of the world's largest integrated health record databases to examine the effectiveness of the Pfizer/BioNTech BNT162B2 vaccine against the Delta variant of SARS-CoV-2 among adolescents.
Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has launched new education, distribution, sampling and reimbursement programs for TIMOPTIC(R) in OCUDOSE(R), the only preservative-free medication for glaucoma available in the United States. Aton acquired the U.S. marketing rights in February to the TIMOPTIC product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle glaucoma.
Western New England College Research Presented at 2nd Pan-American/Iberian Meeting on Acoustics. To keep soldiers in the battlefield healthy, the U.S. Army is exploring new ways to detect harmful bacteria in water.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have successfully combined cellular therapy and gene therapy in a mouse-model system to develop a viable treatment strategy for breast cancer that has spread to a patient's brain.
› Verified 9 days ago